# Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024

NCT07091734

| | |
|---|---|
| **Status** | RECRUITING |
| **Phase** | Phase 2 |
| **Sponsor** | University of Michigan |
| **Enrollment** | 32 participants |

## Key Eligibility Criteria

### Inclusion (6)

- Patients (e18 years old) with a diagnosis of familial partial lipodystrophy (per protocol)
- Hemoglobin A1c e 7.0% at screening and after 12-week run-in period and
- Triglycerides e 200 Milligrams Per Deciliter (mg/dL) at screening and after 12-week run-in period
- Stable body weight during the 3 months prior to screening visit (no gain or loss of \>5% current body weight)
- Diet must have been stable for the prior 3 months (i.e., no major change in macronutrient composition, e.g. starting or stopping diets such as Atkins, paleo, vegetarianism, veganism)

... and 1 more (see full listing online)

### Exclusion (22)

- Diagnosis of generalized lipodystrophy or acquired lipodystrophy
- Having received treatment with a Glucagon-like peptide (GLP) -1 agonist or Tirzepatide within the past 6 months
- History of previous treatment with metreleptin within the past 3 months
- Pancreatitis within the past 3 months
- Patients with a medical history of bone morrow transplant, use of an immune check-point inhibitor, or central nervous system tumor involving the hypothalamus

... and 17 more (see full listing online)

## Locations (1 total)

University of Michigan, Ann Arbor, Michigan, United States